Reneuron Share News (RENE)

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 6 July SVM UK Emerging FundFull Year Results Monday 9 July GroupHalf

ReNeuron Wins GBP1.5 Million Grant For Stem Cell Therapy Development

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it is the "lead" industry participant in a new GBP1.5 million grant from the UK's innovation agency Innovate grant has to

Portugal looks to renewables as March output tops mainland power demand

LISBON, April 3 (Reuters) - For the first time in at least four decades, Portugal's monthly renewable energy production in March exceeded power demand

ReNeuron Now Expects hRPC Stem Cell Trial Data In First Half Of 2019

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it has decided to adjust the number of clinical sites for its CTX stem cell therapy candidate study, and now expects

ReNeuron's first half revenues supported by new drug developments

(ShareCast News) - ReNeuron, an AIM-listed UK based developer of cell-based therapeutics, saw first half revenues double due to a series of successful drug trials. Revenues were £22,000 for the six months ended 30 September 2016 up from £11,000 in the first half of 2015. During the period, the grou

Sunday share tips: ReNeuron, Clipper Logistics, RM Secured Direct Lending

(ShareCast News) - Shares of ReNeuron are for brave investors only, said the Sunday Times' Inside the City column. The stem cell pioneer is scheduled to publish the results of second-phase clinical trials of its potential stroke paralysis treatment alongside its interim results on Monday. ReNeuron's

ReNeuron reports positive progress in clinical trials

(ShareCast News) - UK-based developer of cell-based therapeutics ReNeuron Group provided a trading update ahead of its annual general meeting on Tuesday. The AIM-traded firm reported that all patients have been treated in the PISCES II Phase II clinical trial of its CTX cell therapy candidate for pa

ReNeuron Annual Loss Widens As Product Trials Ramp Up

UK Earnings, Trading Statements Calendar - Next 7 Days

ReNeuron Completes Phase II Stroke Therapy Trial Patient Recruitment

ReNeuron Selects Glioblastoma Multiforme As First Clinical Target

ReNeuron Progressing Blindness Candidate Through Phase I/II Trial

ReNeuron Says First Patient Treated For Retinitis Pigmentosa

ReNeuron moving to purpose-built labs in Wales

(ShareCast News) - ReNeuron's office, laboratory and manufacturing staff were preparing for a space upgrade this week, with the firm announcing it was moving from Guildford to Pencoed in South Wales. The AIM-traded stem cell therapy development company said the new location was purpose-built, and wo

ReNeuron Relocating Headquarters To South Wales Business Park